MSD has launched of JANUVIA® (25 mg, 50 mg, 100 mg daily), a new oral antidiabetic agent for the treatment of type 2 diabetes.

JANUVIA® contains sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor (incretin enhancer) that increases the levels of two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones play a major physiological role in maintaining glucose homeostasis.

Sitagliptin is the most widely prescribed DPP-4 inhibitor worldwide, with over 46 million prescriptions dispensed for the sitagliptin family. JANUVIA® has been launched in 107 countries and boasts clinical data of up to 2 years in duration. Sitagliptin in combination with metformin has a lower risk of hypoglycaemia and leads to weight loss versus a sulphonylurea plus metformin.

Should you have any further queries please contact Sarojini Moodley (Diabetes Franchise Brand and Customer Manager):

sarojini_moodley@merck.com

(011) 655 3117